IGC Pharma Inc (AMEX:IGC) has a beta value of 1.39 and has seen 0.45 million shares traded in the recent trading session. The company, currently valued at $27.09M, closed the recent trade at $0.34 per share which meant it gained $0.03 on the day or 8.70% during that session. The IGC stock price is -167.65% off its 52-week high price of $0.91 and 23.53% above the 52-week low of $0.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.4 million shares traded. The 3-month trading volume is 397.87K shares.
The consensus among analysts is that IGC Pharma Inc (IGC) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.02.
IGC Pharma Inc (AMEX:IGC) trade information
Sporting 8.70% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IGC stock price touched $0.34 or saw a rise of 0.67%. Year-to-date, IGC Pharma Inc shares have moved 1.16%, while the 5-day performance has seen it change 21.35%. Over the past 30 days, the shares of IGC Pharma Inc (AMEX:IGC) have changed 10.32%. Short interest in the company has seen 0.94 million shares shorted with days to cover at 2.53.
IGC Pharma Inc (IGC) estimates and forecasts
The company’s shares have lost -8.31% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -7.36%.
2 analysts offering their estimates for the company have set an average revenue estimate of 305k for the current quarter. 1 have an estimated revenue figure of 326k for the next ending quarter. Year-ago sales stood 295k and 272k respectively for this quarter and the next, and analysts expect sales will grow by 3.39% for the current quarter and -7.36% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.79% over the past 5 years. Earnings growth for 2025 is a modest 54.55% while over the next 5 years, the company’s earnings are expected to increase by 18.29%.
IGC Dividends
IGC Pharma Inc is expected to release its next earnings report on 2025-Feb-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
IGC Pharma Inc (AMEX:IGC)’s Major holders
Insiders own 7.52% of the company shares, while shares held by institutions stand at 20.91% with a share float percentage of 22.61%. Investors are also buoyed by the number of investors in a company, with IGC Pharma Inc having a total of 31.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 0.7 million shares worth more than $0.31 million. As of 2024-06-30, BLACKROCK INC. held 1.1961% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 0.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.28 million and represent 1.0965% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 1.59% shares in the company for having 630.22 shares of worth $0.21 million while later fund manager owns 381.64 shares of worth $0.13 million as of Dec 31, 2024, which makes it owner of about 0.96% of company’s outstanding stock.
